Monday December 17, 2018 21:52

Heathcare Press Release : 22 Dec 2017

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA(R) in Advanced Heathcare—22 Dec 17

- Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III first-line study Merck and Pfizer Inc. (NYSE: PFE) today announced